Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

761.57 +2.66 (+0.35%)
Streaming Delayed Price Updated: 10:25 AM EST, Jan 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 86,523
Open 760.58
Bid (Size) 760.76 (40)
Ask (Size) 762.37 (40)
Prev. Close 758.91
Today's Range 755.54 - 766.64
52wk Range 476.49 - 821.11
Shares Outstanding 91,779,465
Dividend Yield 0.46%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
1 Mooning Stock with Exciting Potential and 2 Facing Headwinds
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial... 
Via StockStory
Topics Economy Energy
News headline image
Regeneron Just Moved From Underperform To Buy - Here's Why ↗
Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) after a surprising shift in analyst sentiment? 
Via Benzinga

Performance

YTD
-1.9%
-1.9%
1 Month
+1.2%
+1.2%
3 Month
+33.0%
+33.0%
6 Month
+39.0%
+39.0%
1 Year
+6.2%
+6.2%

More News

Read More
These S&P500 stocks are moving in today's session ↗
Via Chartmill
News headline image
Why Regeneron (REGN) Stock Is Trading Up Today
Via StockStory
Topics Artificial Intelligence
News headline image
Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
3 Reasons to Avoid REGN and 1 Stock to Buy Instead
Via StockStory
News headline image
Discover which S&P500 stocks are making waves on Tuesday. ↗
Via Chartmill
News headline image
3 Cash-Heavy Stocks We Approach with Caution
Via StockStory
News headline image
The Vaccine Vanguard: Inside Sanofi’s $2.2 Billion Strategic Bet on Dynavax
Via PredictStreet
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Atomic Architect: How University of Washington’s Generative AI Just Rewrote the Rules of Medicine
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Sanofi’s $2.2 Billion Strategic Pivot: Deconstructing the Dynavax Acquisition and the Future of Specialty Medicine
Via PredictStreet
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗
Via Stocktwits
Topics Economy Government
News headline image
Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗
Via Stocktwits
Topics Government World Trade
News headline image
Pfizer Adds to Its Big Bet on Weight Loss Drugs ↗
Via MarketBeat
News headline image
2 Large-Cap Stocks on Our Buy List and 1 We Find Risky
Via StockStory
News headline image
2 Reasons to Buy Regeneron Stock Like There's No Tomorrow ↗
Via The Motley Fool
News headline image
Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
News headline image
3 Low-Volatility Stocks We’re Skeptical Of
Via StockStory
News headline image
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Is Alnylam Pharmaceuticals a Millionaire Maker? ↗
Via The Motley Fool
News headline image
3 Cash-Producing Stocks We Find Risky
Via StockStory
News headline image
Morgan Stanley Downgrades Regeneron (REGN) to Equal-Weight, Citing Fair Valuation and Pipeline Scrutiny
Via MarketMinute
Topics Intellectual Property

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 761.57
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 01/14/26 10:25 AM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 69.90B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 70B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.